Biogen has been trying to build up its R&D pipeline as it faces increased competition for its biggest-selling products like Spinraza (nusinersen) for spinal muscular atrophy (SMA) and its multiple ...

Connecting 80+ EHS experts in pharma and biopharma on the West coast, this year's meeting will address the challenges of ...

The increasing incidence of genetic and rare diseases is a major factor driving revenue growth in the Antisense ...

Describes the nature of a clinical study. Types include: Observational study — observes people and measures outcomes without affecting results. Interventional study (clinical trial) — studies new ...

Nosological limits Unlike epilepsy syndromes for which clinical manifestations are closely tied to a specific genetic cause, such as Dravet syndrome or CDKL5 -related developmental epileptic ...

After the FDA rejection of Zurzuvae in one type of depression and the triple failure of neuro asset dalzanemdor, Sage was ...

The pivotal trial for Neurogene's Rett syndrome gene therapy makes use of baseline controls and a rigorous endpoint that ...

Biogen on Monday said the phase 3 study will evaluate the efficacy and safety of felzartamab compared to the immunosuppressive drug tacrolimus in adults with PMN, with a readout expected in 2029.

Biogen's PROMINENT study will assess felzartamab's efficacy and safety versus tacrolimus for adults with primary membranous nephropathy.

Dravet Syndrome is a severe, life-limiting condition that causes frequent and prolonged seizures.

Biogen plans to advance an experimental treatment for the neuromuscular disease spinal muscular atrophy, or SMA, into registrational studies following encouraging results from an early-stage trial.